Combining mTor inhibitors with rapamycin-resistant T cells: A two-pronged approach to tumor elimination

Molecular Therapy

Volumn 19, Issue 12, 2011, Pages 2239-2248

  Huye, Leslie E ^a   Nakazawa, Yozo ^a   Patel, Mayuri P ^a   Yvon, Eric ^a,b   Sun, Jiali ^a,b   Savoldo, Barbara ^a,b   Wilson, Matthew H ^a,b,c   Dotti, Gianpietro ^a,b   Rooney, Cliona M ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; LYMPHOCYTE ANTIGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOCYTE PROLIFERATION; MTORRR GENE; PRE B LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSPOSON;

EID: 82955195419     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.179     Document Type: Article

References (37)

1. Bollard, CM, Aguilar, L, Straathof, KC, Gahn, B, Huls, MH, Rousseau, A et al. (2004). Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 200:1623-1633. (Pubitemid 40094186)
2. Heslop, HE, Ng, CY, Li, C, Smith, CA, Loftin, SK, Krance, RA et al. (1996). Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551-555. (Pubitemid 26150682)
3. Rooney, CM, Smith, CA, Ng, CY, Loftin, S, Li, C, Krance, RA et al. (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13.
4. Rooney, CM, Smith, CA, Ng, CY, Loftin, SK, Sixbey, JW, Gan, Y et al. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549-1555. (Pubitemid 28406858)
5. Bollard, CM, Huls, MH, Buza, E, Weiss, H, Torrano, V, Gresik, MV et al. (2006). Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma 6:342-347.
6. Pule, MA, Savoldo, B, Myers, GD, Rossig, C, Russell, HV, Dotti, G et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264-1270.
7. Rosenberg, SA and Dudley, ME (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233-240.
8. Sadelain, M, Brentjens, R and Rivière, I (2009). The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 21:215-223.
9. Dotti, G, Savoldo, B and Brenner, M (2009). Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther 20:1229-1239.
10. Lampen, MH and van Hall, T (2011). Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol 23:293-298.
11. Whiteside, TL (2008). The tumor microenvironment and its role in promoting tumor growth. Oncogene 27:5904-5912.
12. Leen, AM, Rooney, CM and Foster, AE (2007). Improving T cell therapy for cancer. Annu Rev Immunol 25:243-265. (Pubitemid 46697909)
13. Hähnel, PS, Thaler, S, Antunes, E, Huber, C, Theobald, M and Schuler, M (2008). Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Res 68:3899-3906.
14. Han, J, Goldstein, LA, Gastman, BR, Rabinovitz, A and Rabinowich, H (2005). Disruption of Mcl-1. Bim complex in granzyme B-mediated mitochondrial apoptosis. J Biol Chem 280:16383-16392. (Pubitemid 40616768)
15. Dotti, G, Savoldo, B, Pule, M, Straathof, KC, Biagi, E, Yvon, E et al. (2005). Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 105:4677-4684. (Pubitemid 40807289)
16. Bollard, CM, Rössig, C, Calonge, MJ, Huls, MH, Wagner, HJ, Massague, J et al. (2002). Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity. Blood 99:3179-3187. (Pubitemid 34525296)
17. Vera, JF, Hoyos, V, Savoldo, B, Quintarelli, C, Giordano Attianese, GM, Leen, AM et al. (2009). Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 17:880-888.
18. Sun, J, Dotti, G, Huye, LE, Foster, AE, Savoldo, B, Gramatges, MM et al. (2010). T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther 18:2006-2017.
19. Liu, K and Rosenberg, SA (2001). Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol 167:6356-6365. (Pubitemid 33081567)
20. Hsu, C, Hughes, MS, Zheng, Z, Bray, RB, Rosenberg, SA and Morgan, RA (2005). Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 175:7226-7234. (Pubitemid 41713417)
21. Jiang, BH and Liu, LZ (2008). Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11:63-76.
22. Mills, JR, Hippo, Y, Robert, F, Chen, SM, Malina, A, Lin, CJ et al. (2008). mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105:10853-10858.
23. Parsa, AT, Waldron, JS, Panner, A, Crane, CA, Parney, I F, Barry, JJ et al. (2007). Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13:84-88. (Pubitemid 46067390)
24. Nepomuceno, RR, Balatoni, CE, Natkunam, Y, Snow, AL, Krams, SM and Martinez, OM (2003). Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 63:4472-4480. (Pubitemid 36951019)
25. Mayerhofer, M, Valent, P, Sperr, WR, Griffin, JD and Sillaber, C (2002). BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100:3767-3775. (Pubitemid 35303950)
26. Easton, JB and Houghton, PJ (2006). mTOR and cancer therapy. Oncogene 25:6436-6446. (Pubitemid 44582287)
27. Skinner, HD, Zheng, JZ, Fang, J, Agani, F and Jiang, BH (2004). Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1α, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 279:45643-45651. (Pubitemid 39491552)
28. Crane, CA, Panner, A, Murray, JC, Wilson, SP, Xu, H, Chen, L et al. (2009). PI (3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene 28:306-312.
29. Nakazawa, Y, Huye, LE, Dotti, G, Foster, AE, Vera, JF, Manuri, PR et al. (2009). Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother 32:826-836.
30. Thomson, AW, Turnquist, HR and Raimondi, G (2009). Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9:324-337.
31. Chen, J, Zheng, XF, Brown, EJ and Schreiber, SL (1995). Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 92:4947-4951.
32. Crane, C, Panner, A, Pieper, RO, Arbiser, J and Parsa, AT (2009). Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother 32:585-592.
33. Fox, CJ, Hammerman, PS and Thompson, CB (2005). The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 201:259-266. (Pubitemid 40189435)
34. Dudley, ME, Yang, JC, Sherry, R, Hughes, MS, Royal, R, Kammula, U et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239.
35. Wang, Y, Camirand, G, Lin, Y, Froicu, M, Deng, S, Shlomchik, WD et al. (2011). Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. J Immunol 186:2809-2818.
36. Suhoski, MM, Golovina, TN, Aqui, NA, Tai, VC, Varela-Rohena, A, Milone, MC et al. (2007). Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 15:981-988. (Pubitemid 46621657)
37. Wilson, MH, Coates, CJ and George, AL Jr (2007). PiggyBac transposon-mediated gene transfer in human cells. Mol Ther 15:139-145. (Pubitemid 46043659)